Ortho Clinical Diagnostics
100 Indigo Creek Drive
Rochester
New York
14626
United States
Tel: 800-828-6316
Fax: 585-453-3660
Website: http://www.orthoclinical.com/
121 articles about Ortho Clinical Diagnostics
-
Quidel Announces Stockholder Approval of Ortho Acquisition and Business Combination
5/16/2022
Quidel Corporation announced that the previously announced acquisition of Ortho Clinical Diagnostics Holdings plc by Quidel and subsequent business combination were approved by Quidel’s stockholders at Quidel’s Special Meeting on May 16, 2022.
-
Ortho Clinical Diagnostics Shareholders Approve Quidel Transaction
5/16/2022
Ortho Clinical Diagnostics Holdings plc announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Company, Quidel, and the other parties thereto.
-
Ortho Clinical Diagnostics Reports First Quarter 2022 ResultsSolid Revenue Performance Drives Financial Results
5/4/2022
Ortho Clinical Diagnostics Holdings plc, one of the world’s largest pure-play in-vitro diagnostics companies, announced financial results for the first quarter ended April 3, 2022.
-
Ortho Clinical Diagnostics Recognized with Fifth Prestigious Edison Award for Highly Accurate COVID-19 SolutionGold Award Recognizes Antibody Test
4/26/2022
Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious Gold 2022 Edison Award for its VITROS® Anti-SARS-CoV-2 IgG Quantitative Test COVID-19 testing solutions, helping labs meet demands of the pandemic with reliable mass-scale testing options.
-
Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2021 Results
2/16/2022
Ortho Clinical Diagnostics Holdings plc, one of the world's largest pure-play in-vitro diagnostics companies, announced financial results for the fourth quarter and fiscal year ended January 2, 2022.
-
Ortho Clinical Diagnostics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
11/23/2021
Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in the 4th Annual Evercore ISI HealthCONx Conference.
-
Ortho Clinical Diagnostics Reports Third Quarter 2021 Results
11/3/2021
Ortho Clinical Diagnostics Holdings plc today announced financial results for the third quarter ended October 3, 2021.
-
Ortho Clinical Diagnostics to Report Third Quarter 2021 Results on November 3, 2021
10/12/2021
Ortho Clinical Diagnostics Holdings plc, one of the world’s largest pure-play in vitro diagnostics companies, announced it will report results for its third quarter 2021 ended October 3, 2021, after the market close on Wednesday, November 3, 2021.
-
Ortho Clinical Diagnostics Announces Launch of New ISXM Capabilities
9/27/2021
Ortho Clinical Diagnostics, one of the world's largest pure-play in vitro diagnostics companies, announced the availability of Immediate Spin Crossmatch on the company's ORTHO VISION® and ORTHO VISION® MAX Analyzers to aid in detecting incompatibility between donors and recipients in blood transfusions.
-
Ortho Clinical Diagnostics Announces Pricing of Secondary Offering of Ordinary Shares
9/9/2021
Ortho Clinical Diagnostics Holdings plc, one of the world’s largest pure-play in vitro diagnostics companies, announced the pricing of the previously announced underwritten secondary offering of 22,000,000 of the Company’s ordinary shares held by a selling shareholder affiliated with The Carlyle Group at a price of $17.50 per ordinary share.
-
Ortho Clinical Diagnostics to Participate in September Investor Conferences
9/3/2021
Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to participate in two upcoming investor conferences.
-
Ortho Clinical Diagnostics Reports Second Quarter 2021 Results
8/4/2021
Ortho Clinical Diagnostics Holdings plc, one of the world's largest pure-play in-vitro diagnostics companies, announced financial results for the second quarter ended July 4, 2021.
-
ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in Canada
7/26/2021
Ortho Clinical Diagnostics, one of the world's largest pure-play in vitro diagnostics companies, announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care with the quality of results expected of an automated platform, is now available in Canada.
-
Ortho Clinical Diagnostics to Report Second Quarter 2021 Results on August 4, 2021
7/23/2021
Ortho Clinical Diagnostics today announced it will report results for its second quarter 2021 ended July 4, 2021, after the market close on Wednesday, August 4, 2021.
-
Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization
7/9/2021
Ortho Clinical Diagnostics, one of the world's largest pure-play in vitro diagnostics companies, announced its VITROS® Anti-SARS-CoV-2 IgG Quantitative Test is the first quantitative COVID-19 IgG antibody test to receive U.S. Food and Drug Administration Emergency Use Authorization.
-
Ortho Clinical Diagnostics Announces Partnership With Thermo Fisher Scientific
7/7/2021
Ortho Clinical Diagnostics today announced its distribution agreement with Thermo Fisher Scientific™ to provide and support MAS™ Quality Controls and LabLink xL™ Quality Assurance Software through Ortho's VITROS® QC Solutions to VITROS® System customers worldwide.*
-
ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in the United States and Puerto Rico
6/7/2021
Ortho Clinical Diagnostics, one of the world's largest pure-play in vitro diagnostics companies, announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care with the quality of results expected of an automated platform, is now available in the United States and Puerto Rico.
-
Ortho Clinical Diagnostics Simultaneously Launches First Quantitative COVID-19 IgG Spike Antibody Test As Well As A Nucleocapsid Antibody Test to Help Differentiate Cause of Antibody Response
5/21/2021
- Ortho is the only company that offers laboratories in the U.S. a quantitative test in combination with a nucleocapsid test - Both new antibody tests help health care teams differentiate the cause of antibodies against SARS-CoV-2 - Ortho's new VITROS ® Anti-SARS-CoV-2 IgG Quantitative Antibody test targets the S1 spike protein and is calibrated to the WHO
-
Ortho Clinical Diagnostics to Present at Upcoming Investor Conferences - May 20, 2021
5/20/2021
Ortho Clinical Diagnostics, one of the world’s largest pure-play in vitro diagnostics companies, announced that members of its management team are scheduled to present in two upcoming investor conferences
-
Ortho Announces Plans to Accelerate COVID-19 Antigen and Antibody Test Development Through New Contract with BARDA and the Department of Defense
3/31/2021
Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play IVD companies, today announced that through its continued partnership with the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Department of Defense, the company been awarded an undefinitized contract which will lead to a $53.7 million contrac